ABBV
AbbVie Inc
265.10$
+0.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.4% | 33.2% | 32.8% | 15.7% | 37.7% | 46.7% | 12.3% | 33.4% | 44.5% | 31.4% | 25.5% | 20.2% | 30.3% | |
| 16.0% | 14.5% | 16.8% | 14.7% | 14.4% | 13.9% | 15.3% | 13.3% | 13.1% | 12.0% | 12.9% | 11.1% | 12.2% | |
| 0.9% | 0.9% | 2.8% | 1.5% | 1.3% | 4.5% | 3.1% | 1.2% | 1.3% | 0.9% | 3.0% | 1.0% | 1.5% | |
| 6.6% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 19.0% | 3.1% | 2.0% | -23.4% | 5.2% | -2.6% | -19.3% | -3.6% | 19.9% | -2.8% | -12.8% | -16.0% | -3.1% | |
| 1.6% | 1.4% | 1.6% | 1.7% | 1.7% | 1.9% | 1.8% | 1.7% | 3.2% | 2.0% | 1.8% | 1.6% | 2.1% | |
| -2.6% | -5.6% | -77.9% | -7.6% | -57.1% | -12.4% | -5.5% | -7.7% | -20.7% | -8.8% | -3.8% | -7.0% | -10.1% | |
| 18.9% | 18.4% | 22.5% | 19.0% | 19.0% | 18.2% | 21.9% | 18.9% | 18.5% | 17.5% | 20.6% | 18.1% | 18.6% | |
| 0.0% | 0.0% | -10.8% | -0.1% | -0.1% | -2.4% | -7.2% | -0.1% | 0.0% | 0.0% | -9.9% | -0.1% | -2.3% | |
| 0.0% | – | – | – | -2.8% | -24.9% | 19.2% | 1.4% | -11.3% | -7.8% | 36.6% | -11.8% | 0.6% | |
| -19.1% | -31.1% | 87.9% | -42.2% | -21.2% | -45.4% | -9.4% | -17.6% | -29.1% | -25.1% | 6.1% | -29.7% | -20.0% | |
| 32.5% | -3.3% | 42.7% | -34.1% | -40.6% | -11.5% | -2.6% | 8.4% | -5.3% | -2.4% | 27.7% | -16.6% | 0.2% | |
| 52.8% | 31.8% | 31.3% | 14.0% | 35.9% | 44.7% | 10.5% | 31.7% | 47.7% | 29.4% | 23.8% | 21.8% | 30.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.